 Genprex Inc said it has opened patient enrollment for its Acclaim-2 clinical trial evaluating the companys lead drug candidate, REQORSA Immunogene Therapy. Acclaim-2 is an open-label, multi-center Phase 12 clinical trial evaluating REQORSA Immunogene Therapy in combination with Keytruda pembrolizumab in patients with late-stage non-small cell lung cancer NSCLC whose disease progressed after treatment with Keytruda. 